October 6th, 2021
Paige receives FDA De Novo clearance for AI to detect prostate cancer
Last year, we partnered with medical startup SFC Fluidics, to build a unique device for those in need of diabetes care. SFC Fluidics was recognized early on by the FDA for healthcare innovation, receiving FDA's Breakthrough Device Designation, and is set to improve the lives of diabetes patients around the world.
Paige Prostate - an AI tool that detects prostate cancer - has become the first of its kind to receive FDA approval. After also earning Breakthrough Device Designation in 2019 and $220M in funding, this software has improved cancer detection by over 7%, decreased false-negative diagnoses by 70%, and false-positive diagnoses by 24%.
We invest in startups that are evolving the healthcare industry, and are proud to work alongside innovators dedicated to improving the well-being of others.